Gilead Sciences

DPHARM panel

CRO

DPHARM: How to address the clinical trial enrollment crisis?

Around 80% of trials don’t meet their enrollment timelines, and fewer than 5% of eligible adult cancer patients participate in trials.

Will Maddox Sep 17, 2026 11:52am

Daniel ODay

CEO O’Day tells Fierce how Gilead reached ‘critical mass’

Sep 16, 2026 8:00am

Graphic image of a human liver in front of a dark green background

Labcorp launches new hepatitis D test

Aug 25, 2026 1:22pm

Metallic arrow symbols illuminated by blue and magenta lights forming a graph on blue and magenta background

Atea’s hepatitis C asset matches Gilead’s Epclusa in phase 3

Jul 28, 2026 9:08am

Red flag on a beach with a storm coming

Study reveals genetic red flags for CAR-T therapy side effects

Jul 24, 2026 2:00pm

Ebola Ebola test

Mapp, Gilead antivirals to be deployed in DRC Ebola trial: WHO

Jun 24, 2026 3:03pm